Labcorp Holdings Inc. (LH) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $266.16, but acceptable to hold if already in. Reasons: Thin upside margin: 4.9%; Below 200-MA (2d, -0.1%).
Labcorp Holdings is a global laboratory services company operating two segments: Dx (diagnostic testing, $10.9B revenue in 2025) and BLS (biopharma lab services, $3.1B), serving patients, healthcare providers, and pharmaceutical companies in ~100 countries. Revenue is generated... Read more
Hold if already holding. Not a fresh buy at $266.16, but acceptable to hold if already in. Reasons: Thin upside margin: 4.9%; Below 200-MA (2d, -0.1%). Chart setup: Death cross but MACD improving, RSI 59. Mixed signals. Hold existing position. Score 5.5/10, moderate confidence.
Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 40d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-06-14Recent Developments — Labcorp Holdings Inc.
Latest news
- NEWS What To Expect From Labcorp’s (LH) Q1 Earnings - StockStory — StockStory neutral
- NEWS LH (Labcorp Holdings Inc.) delivers 7.2% YoY Q4 2025 revenue growth and small EPS beat, shares edge down 0.8%. - Expert — Cổng thông tin điện tử tỉnh Tây Ninh positive
- NEWS All you need to know about Labcorp (LH) rating upgrade to buy - MSN — MSN positive
- NEWS Evercore ISI Group Raises Labcorp Holdings (LH) Price Target to $300 | LH Stock News - GuruFocus — GuruFocus positive
- NEWS Raleigh Capital Management Inc. Sells 11,248 Shares of Labcorp Holdings Inc. $LH - MarketBeat — MarketBeat neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $266.16, but acceptable to hold if already in. Reasons: Thin upside margin: 4.9%; Below 200-MA (2d, -0.1%). Chart setup: Death cross but MACD improving, RSI 59. Mixed signals. Hold existing position. Target $279.11 (+4.9%), stop $253.54 (−5.0%), A.R:R 0.8:1. Score 5.5/10, moderate confidence.
Take-profit target: $279.11 (+4.9% upside). Target $279.11 (+4.9%), stop $253.54 (−5.0%), A.R:R 0.8:1. Stop-loss: $253.54.
Thin upside margin: 4.9%; Below 200-MA (2d, -0.1%).
Labcorp Holdings Inc. trades at a P/E of 23.6 (forward 13.7). TrendMatrix value score: 6.5/10. Verdict: Hold.
28 analysts cover LH with a consensus score of 4.1/5. Average price target: $310.
What does Labcorp Holdings Inc. do?Labcorp Holdings is a global laboratory services company operating two segments: Dx (diagnostic testing, $10.9B revenue...
Labcorp Holdings is a global laboratory services company operating two segments: Dx (diagnostic testing, $10.9B revenue in 2025) and BLS (biopharma lab services, $3.1B), serving patients, healthcare providers, and pharmaceutical companies in ~100 countries. Revenue is generated from test fees billed to MCOs, Medicare/Medicaid, clients, and patients, with nearly all Dx revenues from the U.S. and BLS split 41%/59% U.S./international.